25.40
-0.04 (-0.16%)
| Previous Close | 25.44 |
| Open | 25.50 |
| Volume | 1,300,106 |
| Avg. Volume (3M) | 1,692,630 |
| Market Cap | 1,445,738,624 |
| Price / Sales | 4.28 |
| Price / Book | 4.03 |
| 52 Weeks Range | |
| Earnings Date | 29 Apr 2026 |
| Profit Margin | -36.20% |
| Operating Margin (TTM) | -39.67% |
| Diluted EPS (TTM) | -1.69 |
| Quarterly Revenue Growth (YOY) | 55.30% |
| Total Debt/Equity (MRQ) | 21.02% |
| Current Ratio (MRQ) | 8.95 |
| Operating Cash Flow (TTM) | -83.91 M |
| Levered Free Cash Flow (TTM) | -58.77 M |
| Return on Assets (TTM) | -13.36% |
| Return on Equity (TTM) | -27.62% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Mixed | Bearish |
| Medical Devices (Global) | Mixed | Bearish | |
| Stock | PROCEPT BioRobotics Corporation | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | -0.5 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 1.5 |
| Technical Oscillators | 2.0 |
| Average | 0.88 |
|
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, which are image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Small Growth |
| % Held by Insiders | 4.22% |
| % Held by Institutions | 93.06% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Axa Investment Managers S.A. | 30 Sep 2025 | 1,109,870 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 34.00 (Wells Fargo, 33.86%) | Buy |
| 34.00 (TD Cowen, 33.86%) | Buy | |
| Median | 30.00 (18.11%) | |
| Low | 20.00 (B of A Securities, -21.26%) | Sell |
| Average | 29.43 (15.87%) | |
| Total | 5 Buy, 1 Hold, 1 Sell | |
| Avg. Price @ Call | 24.04 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Baird | 06 Mar 2026 | 30.00 (18.11%) | Hold | 24.22 |
| Truist Securities | 02 Mar 2026 | 30.00 (18.11%) | Buy | 25.90 |
| B of A Securities | 26 Feb 2026 | 20.00 (-21.26%) | Sell | 23.63 |
| Leerink Partners | 26 Feb 2026 | 30.00 (18.11%) | Buy | 23.63 |
| Piper Sandler | 26 Feb 2026 | 28.00 (10.24%) | Buy | 23.63 |
| TD Cowen | 26 Feb 2026 | 34.00 (33.86%) | Buy | 23.63 |
| Wells Fargo | 26 Feb 2026 | 34.00 (33.86%) | Buy | 23.63 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |